Evidence map›Paper›PMID 42244998›Full record

ArticleTheranostics2026

Development and

Michael Willmann, Jens P Bankstahl, Frank M Bengel, Christine Drechsler, Christina Esdar, Kathrin Gläser, Andrea U Lopez, Tatjana Ross, Hanno Schieferstein, Tobias L Ross

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michael WillmannDepartment of Nuclear Medicine, Hannover Medical School, Germany.
Jens P BankstahlDepartment of Nuclear Medicine, Hannover Medical School, Germany.
Frank M BengelDepartment of Nuclear Medicine, Hannover Medical School, Germany.
Christine DrechslerMerck Healthcare KGaA, Darmstadt, Germany.
Christina EsdarMerck Healthcare KGaA, Darmstadt, Germany.
Kathrin GläserMerck Healthcare KGaA, Darmstadt, Germany.
Andrea U LopezMerck Healthcare KGaA, Darmstadt, Germany.
Tatjana RossMerck Healthcare KGaA, Darmstadt, Germany.
Hanno SchiefersteinMerck Healthcare KGaA, Darmstadt, Germany.
Tobias L RossDepartment of Nuclear Medicine, Hannover Medical School, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleMutations in the KRAS gene are some of the most frequent drivers in cancer, including non-small cell lung and colorectal cancer. Covalent inhibitors such as adagrasib, targeting the inactive, GDP-bound form of KRAS-G12C, have shown clinical efficacy but patient selection still depends on invasive biopsies. This study aimed to develop novel fluorine-18 labeled KRAS-G12C inhibitors for noninvasive positron emission tomography (PET) imaging of KRAS mutation status.

methodsThree KRAS-G12C inhibitors were synthesized by modifying the adagrasib scaffold to allow for radiofluorination. Compounds were evaluated for target affinity and specificity using pERK inhibition assays in KRAS-G12C positive MiaPaCa-2 cells and KRAS protein binding assays. Finally,

resultsIn µPET, the tracers showed distinct tumor uptake and biodistribution profiles. Among them, [

conclusions[

Indexed as

Fluorine RadioisotopesPositron-Emission TomographyProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorColorectal NeoplasmsFemaleHumansMiceMice, NudeRadiopharmaceuticalsTissue DistributionFluorine-18Fluorine RadioisotopesKRAS protein, humanProto-Oncogene Proteins p21(ras)RadiopharmaceuticalsCRCfluorine-18KRAS-G12CNSCLCPET imaging

Identifiers

PMID42244998
PMCPMC13231836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.